Gyeonggi-do, South Korea

SaeYeon Lee

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 10.2

ph-index = 2

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: SaeYeon Lee: Innovator in Pharmaceutical Chemistry

Introduction

SaeYeon Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of six patents. His work focuses on innovative compounds that have potential applications in treating various diseases.

Latest Patents

SaeYeon Lee's latest patents include a compound known as 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide. This invention relates to different forms of the compound, methods of making such forms, and pharmaceutical compositions that include these compounds. Another notable patent involves 2-amino-benzimidazole derivatives, which are designed to act as inhibitors for 5-lipoxygenase and/or prostaglandin E synthase. This invention has implications for the treatment of inflammatory diseases, cancer, stroke, and Alzheimer's disease.

Career Highlights

Throughout his career, SaeYeon Lee has worked with esteemed organizations such as Institut Pasteur Korea and Qurient Co., Ltd. His experience in these institutions has allowed him to develop and refine his innovative ideas in pharmaceutical research.

Collaborations

SaeYeon Lee has collaborated with notable colleagues, including Jaeseung Kim and Kiyean Nam. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

SaeYeon Lee is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…